Basisstatistiken
| LEI | 549300NTYWN4CVYSCN32 |
| CIK | 1833141 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cybin Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 1, 2026 |
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York •Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p. |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| May 4, 2026 |
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health •Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK & TORONTO – April 30, 2026 – Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced a collaboration with TARA Mind to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder (“MDD”), while expanding mental health awareness and access within the veteran community. |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| April 30, 2026 |
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference •Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK & TORONTO – April 30, 2026 – Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Eric So, Helus Pharma’s Interim Chief Executive Officer, will be speaking at the 29th Annual Milken Institute Global Conference on a panel entitled “The Next Wave of Health Innovation. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 28, 2026 |
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health •Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK & TORONTO – April 27, 2026 – Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical co |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 23, 2026 |
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan •Addition of globally recognized leaders in translational science and clinical development as the Company advances its pipeline towards key inflection points NEW YORK & TORONTO – April 23, 2026 – Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committe |
|
| April 20, 2026 |
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. |
|
| April 20, 2026 |
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions NEW YORK & TORONTO – April 20, 2026 Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic treatments. |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 16, 2026 |
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs •Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK & TORONTO – April 16, 2026 – Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage ph |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 12, 2026 |
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer •Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industry •Appointment supports Helus Pharma’s continued maturation as the company advances its novel clinical pipeline NEW YORK & TORONTO – March 12, 2026 – Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the appointment of Jill Conwell as Chief People Officer, effective immediately. |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 5, 2026 |
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder Statistically significant (p<0. |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| February 24, 2026 |
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee • In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “designated news release” for the purpose o |
|
| February 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 18, 2026 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc., dba Helus Pharma (the “Company” or “Helus”) 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change February 10, 2026 Item 3. News Release A news release disclosing the material change was disseminated by the Company on February 10, 2026, through BusinessWire. Item 4. Summary of M |
|
| February 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 17, 2026 |
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder •Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7. |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 13, 2026 |
CYBIN INC. DOING BUSINESS AS HELUS PHARMA Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three and nine months ended December 31, 2025 Date: February 12, 2026 CYBIN INC. (doing business as HELUS PHARMA) MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. doing business a |
|
| February 13, 2026 |
CYBIN INC. DOING BUSINESS AS HELUS PHARMA CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2025 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. doing business as Helus Pharma ("Helus Pharma") have been prepared by and are the responsibility of Helus Pharma's management in accordance with International Acco |
|
| February 13, 2026 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Michael Cola, as Chief Executive Officer of Cybin Inc. |
|
| February 13, 2026 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| February 13, 2026 |
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events - - Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (“GAD”) expected in Q1 2026 - This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. |
|
| February 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 10, 2026 |
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution •Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLC •Proven leader in late-stage clinical develop |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 5, 2026 |
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq •Helus Pharma builds on the strong foundation originally created as Cybin Inc. |
|
| January 2, 2026 |
The Nasdaq Stock Market LLC, 1100 New York Ave. NW, Suite 310E, Washington, DC 20005 Eun Ah Choi Senior Vice President Global Head of Regulatory Operations January 2, 2026 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance: This is to certify that on January 2, 2026, The Nasdaq Stock Market (the "Exchang |
|
| January 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40673 CYBIN INC. NYSE American LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 100 King Street West, Sui |
|
| January 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CYBIN INC. (Exact name of registrant as specified in its charter) Ontario N/A (State of incorporation or organization) (I.R.S. Employer Identification No.) 100 King Street West, Suite 5600, Toronto |
|
| December 31, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the "Company") 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change December 30, 2025 Item 3. News Release A news release disclosing the material change was disseminated by the Company on December 30, 2025 through BusinessWire. Item 4. Summary of Material Change On December 30, |
|
| December 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| December 30, 2025 |
Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-292294 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated September 17, 2025, as amended by Amendment No. 1 dated December 19, 2025, to which it relates, as may be further amended or supplemented (the "Base Shelf Prospectus"), and each document deemed to be incorpora |
|
| December 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| December 30, 2025 |
Cybin Initiates At-The-Market Equity Program of up to US$100 Million Cybin Initiates At-The-Market Equity Program of up to US$100 Million TORONTO, CANADA - December 30, 2025 - Cybin Inc. |
|
| December 30, 2025 |
Cybin Inc. Shares of Common Stock EQUITY DISTRIBUTION AGREEMENT Cybin Inc. Shares of Common Stock EQUITY DISTRIBUTION AGREEMENT December 30, 2025 Cantor Fitzgerald Canada Corporation 181 University Avenue, Suite 1500 Toronto, Ontario M5H 3M7 Cantor Fitzgerald & Co. 110 East 59th St, 6th Floor New York, NY 10022 Ladies and Gentlemen: Cybin Inc., a company continued under the Business Corporations Act (Ontario) ("Cybin" or the "Company"), confirms its agreement |
|
| December 30, 2025 |
December 30, 2025 VIA EDGAR Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Dear Sirs/Mesdames: Re: Cybin Inc. (the "Company") Prospectus Supplement dated December 30, 2025 to the Short Form Base Shelf Prospectus dated September 17, 2025 and amended on December 19, 2025 (the "Prospectus Supplement") We hereby consent to the reference to our firm name under the heading "Documen |
|
| December 22, 2025 |
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq TORONTO, CANADA – December 18, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq G |
|
| December 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| December 19, 2025 |
Calculation of Filing Fee Tables F-10 CYBIN INC. Table 1: Newly Registered Securities ☐Not Applicable Security Type Security Class Title Fee Calculation Rule or Instruction Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid 1 Other Common Shares, Warrants, Units, Debt Securities Subscription Receipts 457(o |
|
| December 19, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025. As filed with the Securities and Exchange Commission on December 19, 2025. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYBIN INC. (Exact name of Registrant as specified in its charter) Ontario, Canada (Province or other jurisdiction of incorporation or organization) 2834 (Primary Standard |
|
| December 19, 2025 |
CYBIN INC. as Issuer and [ ] as U.S. Trustee and [ ] as Canadian Trustee Indenture Dated as of [ ] TABLE OF CONTENTS ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.01 Definitions 1 SECTION 1.02 Rules of Construction 9 SECTION 1.03 Compliance Certificates and Opinions 10 SECTION 1.04 Form of Documents Delivered to Trustees 10 SECTION 1.05 Acts of Holders 11 SECTION |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing ("Filer"): Cybin Inc. B. (1) This is [check one]: ☒ an original filing for the Filer ☐ an amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rul |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| December 18, 2025 |
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq TORONTO, CANADA – December 18, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq G |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 26, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the “Company”) 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change October 28, 2025 Item 3. News Release News releases with respect to the material change were disseminated by the Company on October 28 and October 31, 2025 through BusinessWire (collectively, the “News Releases |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 13, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Eric So, as Interim Chief Executive Officer of Cybin Inc. |
|
| November 13, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| November 13, 2025 |
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors - - On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety |
|
| November 13, 2025 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three and six months ended September 30, 2025 Date: November 12, 2025 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s unaudi |
|
| November 13, 2025 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the I |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 12, 2025 |
Cybin to Participate in the Jefferies Global Healthcare Conference in London Cybin to Participate in the Jefferies Global Healthcare Conference in London TORONTO, CANADA – November 12, 2025 – Cybin Inc. |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 6, 2025 |
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Company to host conference call and webcast at 8:00 a. |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 5, 2025 |
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference TORONTO, CANADA – November 5, 2025 – Cybin Inc. |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 3, 2025 |
Cybin to Participate at the 2025 Milken Institute Future of Health Summit - Chief Medical Officer Amir Inamdar to participate in a panel on November 5, 2025 - TORONTO, CANADA – November 3, 2025 – Cybin Inc. |
|
| October 31, 2025 |
CYBIN ANNOUNCES CLOSING OF $175 MILLION REGISTERED DIRECT OFFERING CYBIN ANNOUNCES CLOSING OF $175 MILLION REGISTERED DIRECT OFFERING TORONTO – October 31, 2025 – Cybin Inc. |
|
| October 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| October 29, 2025 |
Placement Agency Agreement October 27, 2025 Cybin Inc. 100 King Street West Suite 5600 Toronto, Ontario Canada M5X 1C9 Attention: Eric So Executive Chair, Interim Chief Executive Officer and President Re: Financing Transaction This letter agreement (this "Agreement") will confirm the arrangements under which Jefferies LLC ("Jefferies"), TD Securities (USA) LLC ("TD Cowen"), Cantor Fitzgerald & Co. |
|
| October 29, 2025 |
October 28, 2025 VIA EDGAR Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Dear Sirs/Mesdames: Re: Cybin Inc. (the "Company") Prospectus Supplement dated October 28, 2025 to the Short Form Base Shelf Prospectus dated September 17, 2025 (the "Prospectus Supplement") We hereby consent to the reference to our firm name under the heading "Documents Filed as Part of the Registratio |
|
| October 29, 2025 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED SEPTEMBER 17, 2025 Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-289139 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated September 17, 2025 to which it relates, as amended or supplemented (the "Base Shelf Prospectus"), and each document deemed to be incorporated by reference into this Prospectus Supplement and the Base Shelf Pro |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| October 29, 2025 |
Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of October 28, 2025, by and between Cybin Inc. |
|
| October 28, 2025 |
CYBIN ANNOUNCES $175 MILLION REGISTERED DIRECT OFFERING - Funding of Clinical Stage Programs with Participation from Prominent Biotech Investors - - Use of Proceeds Includes Repayment of High Trail Convertible Note in Full - TORONTO – October 28, 2025 – Cybin Inc. |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| October 28, 2025 |
COMMON SHARE PURCHASE WARRANT CYBIN INC. FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration No. 333-289139 October 28, 2025 A final base shelf prospectus containing important information relating to the securities offered has been filed with the securities regulatory authorities in each of the provinces and territories of Canada and with the United States Securities and Exchange Commission in the United States. A copy of the |
|
| October 28, 2025 |
PRE-FUNDED COMMON SHARES PURCHASE WARRANT CYBIN INC. FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration No. 333-289139 October 28, 2025 A final base shelf prospectus containing important information relating to the securities offered has been filed with the securities regulatory authorities in each of the provinces and territories of Canada and with the United States Securities and Exchange Commission in the United States. A copy of the |
|
| October 28, 2025 |
FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration No. 333-289139 October 28, 2025 CYBIN ANNOUNCES $175 MILLION REGISTERED DIRECT OFFERING Funding of Clinical Stage Programs with Participation from Prominent Biotech Investors Use of Proceeds Includes Repayment of High Trail Convertible Note in Full TORONTO - October 28, 2025 - Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin" |
|
| September 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 23, 2025 |
X0708 D LIVE 0001833141 CYBIN INC. 100 King St. West, Suite 5600 Toronto A6 ONTARIO, CANADA M5X 1C9 (866) 292-4601 ONTARIO, CANADA None None Corporation true Eric So 100 King St. West Suite 5600 Toronto A6 ONTARIO, CANADA M5X 1C9 Director Executive Officer George Tziras 100 King Street West Suite 560 Toronto A6 ONTARIO, CANADA V5X 1C9 Executive Officer Gabriel Fahel 100 King Street West Suite 5600 |
|
| September 23, 2025 |
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company’s deuterated dimethyltryptamine (“DMT”) program for the treatment of Generalized Anxiety Disorder (“GAD”). |
|
| September 18, 2025 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED SEPTEMBER 17, 2025 Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-289139 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated September 17, 2025 to which it relates, as amended or supplemented (the "Base Shelf Prospectus"), and each document deemed to be incorporated by reference into this Prospectus Supplement and the Base Shelf Pro |
|
| September 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 18, 2025 |
September 17, 2025 VIA EDGAR Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Dear Sirs/Mesdames: Re: Cybin Inc. (the "Company") - Prospectus Supplements each dated September 17, 2025 to the Short Form Base Shelf Prospectus dated September 17, 2025 (collectively, the "Prospectus Supplements") We hereby consent to the reference to our firm name under the headings "Experts" and " |
|
| September 18, 2025 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED SEPTEMBER 17, 2025 Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-289139 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated September 17, 2025 to which it relates, as amended or supplemented (the "Base Shelf Prospectus"), and each document deemed to be incorporated by reference into this Prospectus Supplement and the Base Shelf Pro |
|
| September 17, 2025 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED SEPTEMBER 17, 2025 Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-289139 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated September 17, 2025 to which it relates, as amended or supplemented (the "Base Shelf Prospectus"), and each document deemed to be incorporated by reference into this Prospectus Supplement and the Base Shelf Pro |
|
| September 17, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the "Company") 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change September 2, 2025 Item 3. News Release A news release with respect to the material change was disseminated by the Company on September 2, 2025 through Business Wire. Item 4. Summary of Material Change Effective |
|
| September 17, 2025 |
As filed with the Securities and Exchange Commission on September 17, 2025. As filed with the Securities and Exchange Commission on September 17, 2025. Registration No. 333-289139 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYBIN INC. (Exact name of Registrant as specified in its charter) Ontario, Canada (Province or other jurisdiction of incorporation or organ |
|
| September 17, 2025 |
Calculation of Filing Fee Tables F-10 CYBIN INC. Table 1: Newly Registered Securities ☐Not Applicable Security Type Security Class Title Fee Calculation Rule or Instruction Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Fees Previously Paid Other Common Shares, Warrants, Units, Debt Securities Subscrip |
|
| September 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 17, 2025 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED SEPTEMBER 17, 2025 Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-289139 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated September 17, 2025 to which it relates, as amended or supplemented (the "Base Shelf Prospectus"), and each document deemed to be incorporated by reference into this Prospectus Supplement and the Base Shelf Pro |
|
| September 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 11, 2025 |
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit TORONTO, CANADA – September 11, 2025 – Cybin Inc. |
|
| September 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 9, 2025 |
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - The Phase 2 GAD study has enrolled 36 participants to evaluate the safety and efficacy of CYB004 at 12 weeks after first dose - - Reaffirms top-line data guidance for Q1 2026 - TORONTO, CANADA – September 8, 2025 – Cybin Inc. |
|
| September 4, 2025 |
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference TORONTO, CANADA – September 4, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that George Tzira |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 3, 2025 |
Cybin to Participate in the Cantor Global Healthcare Conference 2025 Cybin to Participate in the Cantor Global Healthcare Conference 2025 TORONTO, CANADA – September 3, 2025 – Cybin Inc. |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 2, 2025 |
Cybin Announces Senior Leadership Changes Doug Drysdale to step down as Chief Executive Officer; Eric So appointed Interim Chief Executive Officer This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025. |
|
| August 27, 2025 |
X0708 D LIVE 0001833141 CYBIN INC. 100 King St. West, Suite 5600 Toronto A6 ONTARIO, CANADA M5X 1C9 (866) 292-4601 ONTARIO, CANADA None None Corporation true Douglas Drysdale 100 King St. West Suite 5600 Toronto A6 ONTARIO, CANADA M5X 1C9 Executive Officer George Tziras 100 King Street West Suite 560 Toronto A6 ONTARIO, CANADA V5X 1C9 Executive Officer Eric So 100 King Street West Suite 5600 Toron |
|
| August 27, 2025 |
X0708 D LIVE 0001833141 CYBIN INC. 100 King St. West, Suite 5600 Toronto A6 ONTARIO, CANADA M5X 1C9 (866) 292-4601 ONTARIO, CANADA None None Corporation true Douglas Drysdale 100 King St. West Suite 5600 Toronto A6 ONTARIO, CANADA M5X 1C9 Executive Officer George Tziras 100 King Street West Suite 560 Toronto A6 ONTARIO, CANADA V5X 1C9 Executive Officer Eric So 100 King Street West Suite 5600 Toron |
|
| August 26, 2025 |
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second study within the CYB003 Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia - - Recently cleared to initiate the EMBRACE study in Ireland, |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 19, 2025 |
Cybin Announces Results of Annual Meeting of Shareholders Cybin Announces Results of Annual Meeting of Shareholders TORONTO, CANADA – August 18, 2025 – Cybin Inc. |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 19, 2025 |
REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102 REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102 In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the annual meeting of the holders of the common shares (the “Shareholders”) of Cybin Inc. (“Cybin”) held on August 18, 2025 (the “Meeting”). There were 90 Shareholders re |
|
| August 14, 2025 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three months ended June 30, 2025 Date: August 13, 2025 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s unaudited condensed i |
|
| August 14, 2025 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the Intern |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 14, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| August 14, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| August 14, 2025 |
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results Cybin continues to make significant progress on its journey to bring breakthrough therapy to patients by delivering on the following key milestones - Received European and United Kingdom Medical and Healthcare Products Regulatory Agency (“MHRA”) approval for EMBRACE, the Company’s second pivotal |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 13, 2025 |
CYBIN INC. Amended and Restated Convertible Note THE SECURITIES REPRESENTED HEREBY AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. |
|
| August 13, 2025 |
OMNIBUS AMENDMENT This Omnibus Amendment (this “Amendment”), dated as of August 12, 2025, is by and between CYBIN INC. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 7, 2025 |
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe, the United Kingdom, and Australia - - European CTA approval to initiate the EMBRACE s |
|
| August 6, 2025 |
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference TORONTO, CANADA – August 6, 2025 – Cybin Inc. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| July 31, 2025 |
CYBIN INC. as Issuer and [ ] as U.S. Trustee and [ ] as Canadian Trustee Indenture Dated as of [ ] TABLE OF CONTENTS ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.01 Definitions 1 SECTION 1.02 Rules of Construction 9 SECTION 1.03 Compliance Certificates and Opinions 10 SECTION 1.04 Form of Documents Delivered to Trustees 10 SECTION 1.05 Acts of Holders 11 SECTION |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing ("Filer"): Cybin Inc. B. (1) This is [check one]: ☒ an original filing for the Filer ☐ an amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rul |
|
| July 31, 2025 |
As filed with the Securities and Exchange Commission on July 31, 2025. As filed with the Securities and Exchange Commission on July 31, 2025. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYBIN INC. (Exact name of Registrant as specified in its charter) Ontario, Canada (Province or other jurisdiction of incorporation or organization) 2834 (Primary Standard Ind |
|
| July 31, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables F-10 CYBIN INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Instruction Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Other Common Shares, Warrants, Units, Debt Securities Subscription Receipts 457(o) Fees to be Paid 1 Unallocated (U |
|
| July 28, 2025 |
CYBIN INC. (the “Corporation”) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS CYBIN INC. (the “Corporation”) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that an annual general meeting (the “Meeting”) of the holders (collectively, the “Shareholders” or individually, a “Shareholder”) of the common shares in the capital of the Corporation (the “Common Shares”) will be held on August 18, 2025 at the hour of 10:00 a.m. (Toronto time). The Meeting will |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 28, 2025 |
CYBIN INC. (the “Corporation”) ABRIDGEMENT CERTIFICATE Pursuant to Section 2.20 of National Instrument 54-101 Reference is made to the annual and special meeting of the shareholders (the “Meeting”) of the Corporation scheduled to be held on August 18, 2025. I, Douglas Drysdale, as the duly appointed Chief Executive Officer of the Corporation, hereby certify on behalf of the Corporation and not in |
|
| July 28, 2025 |
Cybin Inc. Form of Proxy – Annual General Meeting to be held on August 18, 2025 Trader’s Bank Building 702, 67 Yonge Street Toronto ON M5E 1J8 Appointment of Proxyholder I/We being the undersigned holder(s) of Cybin Inc. hereby appoint Eric So, Chair and President or failing this person, Gabriel Fahel, Chief Legal Officer (the “Management Nominees”) OR Print the name of the person you are appointi |
|
| July 28, 2025 |
CYBIN INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS CYBIN INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR July 14, 2025 TABLE OF CONTENTS NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - 2 - MANAGEMENT INFORMATION CIRCULAR - 4 - SOLICITATION OF PROXIES - 4 - VOTING AT THE MEETING - 4 - APPOINTMENT AND REVOCATION OF PROXIES - 5 - EXERCISE OF DISCRETION BY PROXIES - 5 - HOW DO I ATTEND AND PARTICIPATE AT TH |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 17, 2025 |
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia and will commence imminently - - PARADIGMTM comprises two 1 |
|
| July 14, 2025 |
Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-284173 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated August 17, 2023, as amended by Amendment No. 1 dated December 22, 2023, by Amendment No. 2 dated April 8, 2024, and by Amendment No. 3 dated January 6, 2025, to which it relates, as amended or supplemented (th |
|
| July 14, 2025 |
July 14, 2025 VIA EDGAR Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Dear Sirs/Mesdames: Re: Cybin Inc. (the "Company") - Prospectus Supplement dated July 14, 2025 to the Short Form Base Shelf Prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025 (the "Prospectus Supplement") We hereby consent to the reference to our firm name |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 10, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the “Company”) 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change June 30, 2025 Item 3. News Release A news release with respect to the material change was disseminated by the Company on June 30, 2025 through Business Wire. Item 4. Summary of Material Change On June 30, 2025, |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 1, 2025 |
CYBIN INC. Consolidated Financial Statements MARCH 31, 2025 AND 2024 CYBIN INC. Consolidated Financial Statements MARCH 31, 2025 AND 2024 Responsibility for Consolidated Financial Statements The Company’s management is responsible for the integrity and fairness of presentation of these consolidated financial statements. The consolidated financial statements have been prepared by management, in accordance with International Financial Reporting Standards as issued by |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 1, 2025 |
To the United States Securities and Exchange Commission To the United States Securities and Exchange Commission We consent to the incorporation by reference in the Annual Report on Form 40-F of Cybin Inc. |
|
| July 1, 2025 |
Exhibit 99.4 CERTIFICATION I, Doug Drysdale, certify that: 1. I have reviewed this annual report on Form 40-F of Cybin Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the peri |
|
| July 1, 2025 |
Exhibit 99.6 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Cybin Inc. (the “Company”) on Form 40-F for the period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Doug Drysdale, Chief Executive Officer of the Company, certify, purs |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F [ ] Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934 or [X] Annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended March 31, 2025 Commission File Number 001-40673 Cybin Inc. (Exact name of Registrant as specified in its cha |
|
| July 1, 2025 |
CYBIN INC. ANNUAL INFORMATION FORM FOR THE YEAR ENDED MARCH 31, 2025 JUNE 30, 2025 CYBIN INC. ANNUAL INFORMATION FORM FOR THE YEAR ENDED MARCH 31, 2025 JUNE 30, 2025 TABLE OF CONTENTS Page GENERAL 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 1 MARKET AND INDUSTRY DATA 5 REGULATORY 5 GLOSSARY OF TERMS 6 CORPORATE STRUCTURE 14 GENERAL DEVELOPMENT OF THE BUSINESS 16 DESCRIPTION OF THE BUSINESS 27 RISK FACTORS 76 DIVIDEND AND DISTRIBUTIONS 110 DESCRIPTION OF CAPITAL STRUCT |
|
| July 1, 2025 |
CYBIN ANNOUNCES FINANCING OF UP TO US$500 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE DEBENTURES - Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 - TORONTO – June 30, 2025 - Cybin Inc. |
|
| July 1, 2025 |
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”), dated as of June 30, 2025, is between CYBIN INC. |
|
| July 1, 2025 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 30, 2025 is made by and between High Trail Special Situations LLC , a High Trail Special Situations LLC, 290 Harbor Drive, 3rd Floor Stamford, CT 06902 Attn: Capital Solutions (the “Investor”), and Cybin Inc. |
|
| July 1, 2025 |
Exhibit 99.7 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Cybin Inc. (the “Company”) on Form 40-F for the period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Greg Cavers, Chief Financial Officer of the Company, certify, pursua |
|
| July 1, 2025 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the year ended March 31, 2025 Date: June 30, 2025 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s audited consolidated financial |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 1, 2025 |
Exhibit 99.5 CERTIFICATION I, Greg Cavers, certify that: 1. I have reviewed this annual report on Form 40-F of Cybin Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period |
|
| July 1, 2025 |
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights - Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients1 - - Strengthened commercial preparations and |
|
| July 1, 2025 |
Cybin Inc. INCENTIVE COMPENSATION RECOVERY POLICY August 2023 CYBIN INC. INCENTIVE COMPENSATION RECOVERY POLICY 1.Introduction. The Board of Directors of Cybin Inc. (the “Company”) believe that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The B |
|
| July 1, 2025 |
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”), dated as of June 30, 2025, is between CYBIN INC. |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 13, 2025 |
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder (“MDD”) with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) - - Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company’s commercialization and manufacturing capabilities - - Positive regulatory signals from U. |
|
| June 12, 2025 |
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference TORONTO, CANADA – June 12, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drys |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 11, 2025 |
Cybin to Participate in the 2025 Psychedelic Science Conference - Cybin CEO Doug Drysdale to participate in a panel discussion titled “The Home Stretch: Pivotal Trials and Preparing for Launch” on June 19, 2025 - TORONTO, CANADA – June 11, 2025 – Cybin Inc. |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 3, 2025 |
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder - Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine (“DMT”) and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 - - Cybin’s growing intellectual property portfolio comprises more t |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 22, 2025 |
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 TORONTO, CANADA – May 22, 2025 – Cybin Inc. |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 20, 2025 |
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - U.S. Food and Drug Administration (“FDA”) Commissioner identifies psychedelic drug development as a top agency priority in an effort to address unmet needs in mental health - - Calls for FDA to be open to innovative treatments that show promise, even when they challenge trad |
|
| May 15, 2025 |
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Thermo Fisher Scientific, the world leader in serving science, is providing Phase 3 capsule clinical supply and will support future commercial manufacturing efforts for CYB003 - - Production of both drug substance and drug product will be per |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 14, 2025 |
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase TORONTO, CANADA – May 14, 2025 – Cybin Inc. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 8, 2025 |
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 - - Cybin’s growing intellectual property portfolio comprises more than 80 granted patents and over 230 pending a |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 1, 2025 |
Cybin to Participate at the 28th Annual Milken Institute Global Conference - Doug Drysdale, CEO, to appear on panel entitled “The Global Landscape and Opportunities for Medical Breakthroughs,” on May 5, 2025 - TORONTO, CANADA – May 1, 2025 – Cybin Inc. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 23, 2025 |
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks |
|
| April 21, 2025 |
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline - - Osmind is a leading service provider to psychiatry practices in the U. |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 14, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the "Company") 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change February 10, 2025 Item 3. News Release A news release disclosing the material change was disseminated by the Company on February 10, 2025 through BusinessWire. Item 4. Summary of Material Change On February 10, |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110258.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 11, 2025 |
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) - - PARADIGM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE |
|
| February 11, 2025 |
February 10, 2025 VIA EDGAR Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Dear Sirs/Mesdames: Re: Cybin Inc. (the "Company") Prospectus Supplement dated February 10, 2025 to the Short Form Base Shelf Prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025 (the "Prospectus Supplement") We hereby consent to the reference to our firm |
|
| February 11, 2025 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the In |
|
| February 11, 2025 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three and nine months ended December 31, 2024 Date: February 10, 2025 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s unaudi |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 11, 2025 |
Cybin Inc. Shares of Common Stock EQUITY DISTRIBUTION AGREEMENT Cybin Inc. Shares of Common Stock EQUITY DISTRIBUTION AGREEMENT February 10, 2025 Cantor Fitzgerald Canada Corporation 181 University Avenue, Suite 1500 Toronto, Ontario M5H 3M7 Cantor Fitzgerald & Co. 110 East 59th St, 6th Floor New York, NY 10022 Ladies and Gentlemen: Cybin Inc., a company continued under the Business Corporations Act (Ontario) ("Cybin" or the "Company"), confirms its agreement |
|
| February 11, 2025 |
SUPPL 1 formsuppl.htm FORM SUPPL Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-284173 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated August 17, 2023, as amended by Amendment No. 1 dated December 22, 2023, by Amendment No. 2 dated April 8, 2024, and by Amendment No. 3 dated January 6, 2025, to which it relate |
|
| February 11, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| February 11, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| January 15, 2025 |
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance - - First program member is Segal Trials, a preferred provider for leading pharmaceutical companies globally - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of patients - TORONTO, CANADA – January 15, 2025 – Cybin Inc. |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 13, 2025 |
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (“MDD”) - - Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of MDD – - Received U. |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 10, 2025 |
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 EX-99.1 2 a01-09x2025lythamhealthcar.htm EX-99.1 Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 TORONTO, CANADA – January 9, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-gener |
|
| January 8, 2025 |
As filed with the Securities and Exchange Commission on January 7, 2025. As filed with the Securities and Exchange Commission on January 7, 2025. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYBIN INC. (Exact name of Registrant as specified in its charter) Ontario, Canada (Province or other jurisdiction of incorporation or organization) 2834 (Primary Standard I |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing ("Filer"): Cybin Inc. B. (1) This is [check one]: ☒ an original filing for the Filer ☐ an amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rul |
|
| January 8, 2025 |
EX-FILING FEES Calculation of Filing Fee Tables FORM F-10 (Form Type) CYBIN INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(3) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration |
|
| January 8, 2025 |
CYBIN INC. as Issuer and [ ] as U.S. Trustee and [ ] as Canadian Trustee Indenture Dated as of [ ] TABLE OF CONTENTS ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.01 Definitions 1 SECTION 1.02 Rules of Construction 9 SECTION 1.03 Compliance Certificates and Opinions 10 SECTION 1.04 Form of Documents Delivered to Trustees 10 SECTION 1.05 Acts of Holders 11 SECTION |
|
| December 10, 2024 |
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results - Poster presentations highlight clinical data across Cybin’s CYB003 deuterated psilocin and DMT programs - TORONTO, CANADA – December 10, 2024 – Cybin Inc. |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| December 4, 2024 |
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 TORONTO, CANADA – December 4, 2024 – Cybin Inc. |
|
| December 3, 2024 |
CYBN / Cybin Inc. / TANG CAPITAL MANAGEMENT LLC Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 3, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Shares, no par value, of Cybin Inc. and further agree to the filing of this agreement as an exhib |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 18, 2024 |
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared |
|
| November 14, 2024 |
CYBN / Cybin Inc. / Logos Global Management LP Passive Investment SC 13G/A 1 cybn13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Cybin Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 23256X100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 14, 2024 |
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - Company to host conference call and webcast at 8:00 a. |
|
| November 14, 2024 |
CYBN / Cybin Inc. / Point72 Asset Management, L.P. - CYBIN INC. Passive Investment SC 13G/A 1 p24-3230sc13ga.htm CYBIN INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cybin Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23256X407 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 13, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| November 13, 2024 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three and six months ended September 30, 2024 Date: November 12, 2024 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s unaudi |
|
| November 13, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 13, 2024 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the I |
|
| November 13, 2024 |
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - PARADIGM TM program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - APPROACH TM: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans with Major Depressive Disorder has been initiated and will enroll 220 patients at 36 clinical sites across the U. |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 1, 2024 |
Cybin to Participate at the 2024 Milken Institute Future of Health Summit - CEO Doug Drysdale to speak on panel about novel approaches to mental health treatments on November 13, 2024 - TORONTO, CANADA – October 31, 2024 – Cybin Inc. |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| October 24, 2024 |
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - The Company is evaluating non-hallucinogenic dosing of CYB005 preclinical candidate molecules for the treatment of CNS disorders - - Cybin’s sector-leading intellectual property portfolio now includes over 70 granted patents and more than 220 patent applications pending - TORONTO, CA |
|
| October 3, 2024 |
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 TORONTO, CANADA – October 3, 2024 – Cybin Inc. |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| October 1, 2024 |
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program - Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder (“MDD”) imminently - - Cybin welcomes Dr. |
|
| September 24, 2024 |
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit TORONTO, CANADA – September 24, 2024 – Cybin Inc. |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 20, 2024 |
Cybin Provides Corporate Update on Upcoming Clinical Milestones - Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder (“MDD”) expected imminently - - 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 - - Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder (“GAD”) expected year-end 2024 or early Q1 2025 - - Strengthened R&D team with addition of experienced drug development leaders Dr. |
|
| September 20, 2024 |
CYBIN INC LETTER OF TRANSMITTAL CYBIN INC LETTER OF TRANSMITTAL TO: ODYSSEY TRUST COMPANY The undersigned hereby represents and warrants that the undersigned is the owner of the number of common shares (“common shares”) of Cybin Inc. |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 20, 2024 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Cybin Inc. |
|
| September 20, 2024 |
certificateandarticlesof Ministry of Public and Business Service Delivery Ministère des Services au public et aux entreprises Certificate of Amendment Certificat de modification Business Corporations Act Loi sur les sociétés par actions CYBIN INC. |
|
| September 20, 2024 |
Cybin Announces Completion of Previously Announced Share Consolidation Cybin Announces Completion of Previously Announced Share Consolidation TORONTO, CANADA – September 19, 2024 – Cybin Inc. |
|
| September 4, 2024 |
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference TORONTO, CANADA – September 4, 2024 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 29, 2024 |
REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102 REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102 In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the annual and special meeting of the holders of the common shares (the “Shareholders”) of Cybin Inc. (“Cybin”) held on August 27, 2024 (the “Meeting”). There were 87 Sha |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 28, 2024 |
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation TORONTO, CANADA – August 27, 2024 – Cybin Inc. |
|
| August 27, 2024 |
CYBN / Cybin Inc. / Logos Global Management LP Passive Investment SC 13G 1 cybn13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Cybin Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 23256X100 (CUSIP Number) March 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| August 19, 2024 |
CYBIN INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS CYBIN INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR July 24, 2024 TABLE OF CONTENTS MANAGEMENT INFORMATION CIRCULAR 4 SOLICITATION OF PROXIES 4 VOTING AT THE MEETING 4 APPOINTMENT AND REVOCATION OF PROXIES 5 EXERCISE OF DISCRETION BY PROXIES 5 HOW DO I ATTEND AND PARTICIPATE AT THE MEETING? 6 ADVICE TO BENEFICIAL SHAREHOLDERS 6 NOTE TO NON-OBJECTING |
|
| August 19, 2024 |
CYBIN INC. Form of Proxy – Annual and Special Meeting to be held on August 27, 2024 Trader’s Bank Building 702, 67 Yonge Street Toronto ON M5E 1J8 Appointment of Proxyholder I/We being the undersigned holder(s) of common shares of Cybin Inc. (the “Corporation”) hereby appoint Eric So, Chair and President, or failing this person, Gabriel Fahel, Chief Legal Officer (the “Management Nominees”) OR Pri |
